By Jonathan Smith at Labiotech.eu
Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and societal awareness could spell fresh investments in the coming years.
Over the last decade, pressure has been mounting on healthcare systems as infectious microbes become harder and harder to fight with antibiotics. Some strains of bacteria, including Clostridium difficile, are seen as urgent threats that need a better range of antibiotic treatments.… continue reading>>